Potential drugs for repurposing in Alzheimer’s disease
Contributors
Abhinav Anand
Keywords
Proceeding
Track
General Track
License
Copyright (c) 2026 Sustainable Global Societies Initiative

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Abstract
Drug repurposing offers a practical route to investigating treatments for Alzheimer's disease, but an established indication does not guarantee benefit in a different patient population. This narrative review examines human evidence for metformin, lithium, liraglutide, semaglutide, intranasal insulin, sildenafil, nilotinib and minocycline. Relevant PubMed records and journal reports were identified through targeted searches, with evidence checked on 14 October 2026. Clinical outcomes were considered alongside study design, biomarker findings and tolerability. Small trials identified selective cognitive signals, whereas larger studies often failed to demonstrate benefit. Observational associations also varied with the population and comparator studied. These differences prevent a simple ranking of candidates and argue against treating laboratory or biomarker changes as proof of clinical effectiveness. Further research should establish brain exposure, identify appropriate disease stages and measure outcomes that matter to patients. Repurposing remains a useful research strategy, but the evidence reviewed here does not support routine use of these medicines specifically to slow Alzheimer's progression